VASTox prepares to commence next phase of clinical development for two neuro-disorder drug programmes
Both programmes were previously owned by DanioLabs, which was acquired by VASTox in March 2007, and the progression of these clinical programmes follows a successful period of integration into the scientific and commercial infrastructure of the enlarged Company.
In the seborrhoea programme, recruitment for the next Phase I clinical trial is underway and VASTox expects to begin this in mid 2007. In sialorrhoea, a combined Phase I/II clinical trial in patients will commence in the fourth quarter of 2007.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.